--根据商业信息公司GBI Research近日发布的新研究报告，全球2型糖尿病市场预计将以10.2%的复合年增长率（CAGR）增长，从2012年的204亿美元增长至2019年的388亿美元。
该报告指出，目前美国拥有最高的市场份额，将以11.6%的复合年增长率增长，从2012年的127亿美元增长至2019年的272亿美元。其次是欧盟5大市场（英国、法国、德国、意大利、西班牙），年复合增长率为6.8%，将从45亿美元增长至71亿美元。
这一增长，是由于在相对较新的药物类别中预期的产品获批，如GLP-1受体激动剂、DPP-4和SGLT-2抑制剂。这些昂贵的药物类有望攫取可观的市场份额，预计将导致更为强劲的市场增长水平。
此外，由于肥胖症患者的增加以及人类寿命的延长，2型糖尿病患者数目也有望上升。
然而，在2型糖尿病患者中广泛应用的2类药物，磺脲类和二甲双胍类药物，被仿制药和低成本产品的强烈渗透，将是2型糖尿病市场增长的潜在主要障碍。
英文原文：Global type 2 diabetes market to reach $38.8 billion by 2019
NEW YORK (GBI Research), 24 September 2013 -- The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 10.2%, forecasts business intelligence provider GBI Research.
The company’s latest report* states that the US currently has the highest market share, which will rise from $12.7 billion in 2012 to $27.2 billion by 2019, at a CAGR of 11.6%, followed by the top five EU markets (the UK, France, Germany, Italy and Spain), which will grow from $4.5 billion to $7.1 billion, at a CAGR of 6.8%.
This increase, according to GBI Research, is due to the anticipated approval of products in relatively novel treatment classes, such as GLP-1 agonists, DPP-4 and SGLT-2 inhibitors. Should these expensive drug classes capture substantial market shares, this would be expected to result in an even more robust level of market growth.
Furthermore, due to the increase in the number of obesity cases and with people living longer, the prevalence of type 2 diabetes is also expected to rise.
Dominic Trewartha, GBI Research’s Associate Analyst, says: “The strong forecast for the type 2 diabetes market is reliant upon the ability of late-stage pipeline drugs, such as gemigliptin, to reach expectations created by promising clinical trial results, and of newly marketed products, including Nesina and Tradjenta, to capture a significant share of the market. In order to do this, they will need to balance clinical efficacy with safety and tolerability profiles.”
However, the sulfonylureas and metformin classes, both widely used among type 2 diabetes patients, are strongly penetrated by generic and low-cost products, presenting a potential major barrier to the market.
*Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019
This report provides an in-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. It includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.